美多芭联合息宁对帕金森病患者症状波动 及便秘的影响

目的评价美多芭联合息宁分服对帕金森病患者症状波动和便秘的影响。方法选取我院帕金森病患者104例,随机分为分服组与对照组各52例。分服组患者采用美多芭联合息宁治疗,对照组患者单纯采用美多芭治疗。在患者入组时、治疗第4周和治疗第8周时分别比较两组患者日记记录的"开"和"关"时间以及帕金森病统一评分量表Ⅲ(UPDRS-Ⅲ)、PAC-SYM评分和PDQ-39评分结果。结果治疗后两组患者均延长了"开"时间,缩短"关"时间。分服组在治疗第4周和第8周时延长"开"时间、缩短"关"时间情况优于对照组,差异均有统计学意义(均P0.05)。治疗后两组患者UPDRS-Ⅲ评分均有所改善。治疗第4周时分服组患者UPDRS-Ⅲ评分、PAC-SYM评分与对照组比较差异无统计学意义(均P0.05);治疗第8周时分服组患者UPDRS-Ⅲ和PAC-SYM评分均低于对照组,差异有统计学意义(均P0.05)。两组患者治疗后PDQ-39评分均降低,治疗第4周时分服组患者PDQ-39评分与对照组相比差异无统计学意义(P0.05);治疗第8周时分服组患者PDQ-39评分低于对照组,差异有统计学意义(P0.05)。结论美多芭联合息宁分服对帕金森病患者症状波动和便秘的改善均优于单用美多芭治疗,能提高患者生活质量,值得临床推广。

The effect of Madopar combined with Sinemet CR on symptom fluctuation and constipation of patients with Parkinson's disease

Abstract: Objective To evaluate the effects of Madopar combined with Sinemet CR on symptom fluctuation and constipation of patients with Parkinson''s disease. Methods A total of 104 patients with Parkinson''s disease were randomly divided into the observation group or the control group, 52 cases in each group. The observation group was treated with Madopar combined with Sinemet CR. The control group was treated with Madopar alone. The "on" and "off" time, Parkinson''s Disease Unified Rating Scale III (UPDRS-III) score, PAC-SYM score, and PDQ-39 score at enrollment (baseline), 4 and 8 weeks after treatment were compared between the two groups. Results After treatment, the "on" time prolonged while the "off" time shortened in both groups; the observation group was superior to the control group at 4 and 8 weeks after treatment, with significant differences (all P<0.05). After treatment, the UPDRS-III scores improved in both groups. There were no significant differences in the UPDRS-III score and PAC-SYM score between groups at the 4th week (all P>0.05). At the 8th week, the scores of UPDRS-III and PAC-SYM in the observation group were significantly lower than those in the control group respectively (all P<0.05). The PDQ-39 scores of both groups decreased after treatment. There was no significant difference in the PDQ-39 scores between two groups at the 4th week (P>0.05). At the 8th week, the PDQ-39 score in the observation group was significantly lower than that in the control group (P<0.05). Conclusion: The combination of Madopar and Sinemet CR is superior to Madopar alone for improving the symptom fluctuations and constipation, and can therefore improve the quality of life of patients with Parkinson''s disease.